Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19. Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Drug Development Programs Also Moving Forward
ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease today announced the signing of a binding letter of intent to collaborate
Contact Us
- 707-OTC-WIRE (707-682-9473)
- cs@otcprwire.com
Recent Comments